Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Up 5,048.9% in May

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 315,885 shares, a growth of 5,048.9% from the May 14th total of 6,135 shares. Based on an average daily trading volume, of 1,158,189 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.9% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genenta Science in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Get Genenta Science alerts:

Read Our Latest Report on GNTA

Hedge Funds Weigh In On Genenta Science

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new position in Genenta Science during the third quarter worth $41,000. SmartHarvest Portfolios LLC bought a new position in Genenta Science during the fourth quarter worth $26,000. Alyeska Investment Group L.P. bought a new position in Genenta Science during the fourth quarter worth $328,000. Norges Bank bought a new position in Genenta Science during the fourth quarter worth $337,000. Finally, Weiss Asset Management LP bought a new position in Genenta Science during the fourth quarter worth $480,000. Institutional investors own 15.13% of the company’s stock.

Genenta Science Price Performance

Shares of Genenta Science stock opened at $1.65 on Thursday. Genenta Science has a 1-year low of $0.55 and a 1-year high of $10.00. The firm has a fifty day simple moving average of $0.87 and a 200-day simple moving average of $1.10. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16.

Genenta Science (NASDAQ:GNTA – Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.28.

Genenta Science Company Profile

(Get Free Report)

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.

Read More

• Five stocks we like better than Genenta Science
• Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
• This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
• Intel Is the Market’s Most Mispriced AI Hedge
• The Biggest Opportunity From SpaceX’s IPO May Surprise You

Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.